Motilin: The Stomach's Cleaning Wave Peptide
Gut Peptide Hormones
90 Minute Cycles
Every 90 to 120 minutes during fasting, motilin triggers a powerful wave of contractions that sweeps undigested material from the stomach through the small intestine. This is the migrating motor complex.
De Smet et al., Pharmacology and Therapeutics, 2009
De Smet et al., Pharmacology and Therapeutics, 2009
View as imageBetween meals, when the stomach and small intestine are empty of food, a coordinated wave of muscular contractions begins in the stomach and propagates through the entire length of the small intestine over approximately 90 to 120 minutes. This is the migrating motor complex (MMC), and it functions as the digestive tract's housekeeping system, sweeping residual food particles, bacteria, and cellular debris toward the colon. The peptide hormone that initiates this process is motilin, a 22-amino-acid peptide released cyclically by specialized enteroendocrine cells (Mo cells) in the duodenum and jejunum during fasting.[1]
Motilin is clinically relevant for two reasons. First, disruption of the MMC is a feature of gastroparesis, small intestinal bacterial overgrowth (SIBO), and functional dyspepsia, all conditions where the stomach and intestines fail to clear contents properly. Second, the macrolide antibiotic erythromycin acts as a motilin receptor agonist at sub-antimicrobial doses, a pharmacological accident that turned an antibiotic into one of the most widely used prokinetic agents. This article covers the biology of motilin, its role in the MMC, the erythromycin connection, and the search for motilin-based gastroparesis therapeutics. For the broader landscape of digestive peptides, see Every Peptide Hormone Your Gut Produces: A Complete Guide. For the closely related hunger hormone, see Ghrelin and Gut Motility: The Hunger Hormone's Digestive Role.
Key Takeaways
- Motilin is released cyclically every 90-120 minutes during fasting and initiates Phase III of the migrating motor complex, the powerful contractile wave that clears the stomach and small intestine (De Smet et al., Pharmacology and Therapeutics, 2009)
- Ghrelin and motilin share structural homology and their receptors belong to the same GPCR family; both stimulate gastric contractions but through distinct receptor systems and with different physiological contexts (Chen et al., Current Opinion in Pharmacology, 2012)
- Erythromycin activates motilin receptors at sub-antimicrobial doses, producing gastric contractions and accelerating gastric emptying, making it the most commonly used prokinetic for acute gastroparesis (De Smet et al., 2009)
- Kitazawa et al. (2016) demonstrated that motilin and ghrelin produce distinct contractile patterns in isolated gastrointestinal smooth muscle, with motilin producing sustained contractions and ghrelin producing phasic contractions
- A 2025 study showed that motilin stimulates food intake in Suncus murinus (a motilin-expressing animal model), linking the "cleaning wave" peptide to appetite regulation for the first time (Huang et al., 2025)
- GLP-1 receptor agonists slow gastrointestinal motility, and a 2025 study using wireless motility capsules demonstrated measurable delays across the entire gut, raising concerns about GLP-1-induced gastroparesis (Cymbal et al., 2025)
What is motilin?
Motilin is a 22-amino-acid peptide hormone encoded by the MLN gene. It is produced and released by Mo cells, a type of enteroendocrine cell concentrated in the duodenum and proximal jejunum. Motilin acts through the motilin receptor (MLNR), a G protein-coupled receptor expressed on smooth muscle cells and enteric neurons throughout the gastric antrum and upper small intestine.[1]
The peptide is released in a cyclical pattern during fasting, with plasma motilin levels peaking just before each Phase III contraction of the MMC and falling after the contraction wave passes. This pulsatile release pattern is tightly coupled to the MMC cycle, though whether motilin initiates Phase III or is released in response to neural signals that also trigger Phase III has been debated. The current consensus, supported by pharmacological studies showing that exogenous motilin administration triggers premature Phase III contractions, favors motilin as a direct initiator.[2]
Motilin expression is limited to certain species. Humans, dogs, rabbits, and the Asian house shrew (Suncus murinus) express functional motilin and motilin receptors. Rats and mice do not, which has historically complicated preclinical research on motilin-based therapies. This species limitation explains why ghrelin (which is expressed in all mammals) has been studied more extensively than motilin in rodent models, despite motilin's direct clinical relevance to human gastroparesis.
The structural relationship between motilin and ghrelin extends to their receptors. The motilin receptor (MLNR/GPR38) and the ghrelin receptor (GHSR1a) share approximately 52% amino acid sequence identity and belong to the same GPCR subfamily. This structural kinship explains why some ghrelin receptor agonists exhibit weak cross-reactivity with the motilin receptor and vice versa, and has led researchers to explore whether dual motilin-ghrelin receptor agonists might be more effective prokinetic agents than compounds targeting either receptor alone.
The migrating motor complex
The MMC is a cyclical pattern of gastrointestinal motility that occurs during fasting, typically divided into four phases.
Phase I (quiescent period, 40-60% of cycle): minimal contractile activity. The gut is essentially resting.
Phase II (irregular contractions, 20-30% of cycle): intermittent, non-propagating contractions that gradually increase in frequency and amplitude. This phase involves progressive mixing and movement of residual contents.
Phase III (activity front, 5-10 minutes): a burst of high-amplitude, rhythmic contractions that propagate from the stomach (or proximal duodenum) through the entire small intestine. This is the "cleaning wave" that motilin triggers. The contractions are strong enough to move any remaining solid material, mucus, dead cells, and bacteria toward the colon.
Phase IV (brief transition): a short period of declining activity before the cycle returns to Phase I.
The entire cycle takes 90 to 120 minutes in humans. Eating terminates the MMC immediately and switches the gut to a fed-state motility pattern driven by different peptides and neural signals. The MMC resumes after the digestive period is complete.
The clinical significance of the MMC lies in its housekeeping function. Without regular Phase III contractions, bacteria that are normally swept into the colon can accumulate in the small intestine, leading to SIBO. Food residue that should be cleared between meals remains in the stomach, contributing to gastroparesis symptoms (nausea, early satiety, bloating). Disrupted MMC cycling is documented in diabetes-associated gastroparesis, post-surgical dysmotility, and idiopathic gastroparesis.
Motilin and ghrelin: structural cousins
Chen et al. (2012) reviewed the relationship between motilin and ghrelin, two peptides that share structural homology and whose receptors belong to the same GPCR subfamily.[2] Asakawa et al. (2001) had originally noted ghrelin's structural resemblance to motilin when ghrelin was first characterized.[3]
Both peptides stimulate gastric contractions, but in different physiological contexts. Motilin drives the fasting MMC. Ghrelin rises before meals to stimulate appetite and gastric motility in preparation for eating. Kitazawa et al. (2016) demonstrated this distinction directly using isolated gastrointestinal smooth muscle strips, showing that motilin produces sustained, tonic contractions while ghrelin produces phasic, rhythmic contractions, reflecting their different roles in fasting versus pre-prandial motility.[4]
Depoortere et al. (2005) compared the gastroprokinetic effects of ghrelin, GHRP-6, and motilin in rats in vivo and in vitro. Despite the species limitation (rats lack the motilin receptor), the study provided comparative pharmacological data on how these structurally related peptides activate gastric motility through overlapping but distinct signaling pathways.[5]
The motilin-ghrelin connection has therapeutic implications. Because ghrelin receptor agonists work in species that lack motilin receptors (including rats and mice), they have been more amenable to preclinical development. Shin et al. (2015) reviewed the therapeutic applications of ghrelin agonists for gastroparesis, noting that drugs targeting the ghrelin receptor pathway could indirectly address some of the same motility deficits that motilin deficiency causes.[6]
Erythromycin: the accidental prokinetic
The discovery that erythromycin activates motilin receptors was accidental. Clinicians noticed that patients receiving erythromycin for infections developed gastrointestinal side effects, particularly abdominal cramping and diarrhea, caused by increased gut motility. Investigation revealed that erythromycin binds to the motilin receptor and activates it at concentrations well below those needed for antimicrobial activity.[1]
This finding transformed erythromycin from an antibiotic with gastrointestinal side effects into a prokinetic drug given specifically for its gastrointestinal effects. At low doses (typically 50-100 mg intravenously or 250 mg orally, versus 500 mg-2 g for antibiotic use), erythromycin triggers gastric contractions and accelerates gastric emptying. It is now the most commonly used prokinetic agent for acute gastroparesis, particularly in hospitalized patients who need to resume oral nutrition.
The limitations of erythromycin as a prokinetic are substantial. Tachyphylaxis (loss of effectiveness with repeated dosing) develops within days to weeks as motilin receptors downregulate. The antibiotic properties at any dose carry the risk of antibiotic resistance and disruption of the intestinal microbiome. Cardiac QT prolongation is a risk, particularly in combination with other QT-prolonging drugs. And the oral bioavailability of erythromycin for prokinetic purposes is variable and inconsistent.
These limitations have driven the search for selective motilin receptor agonists that lack antibiotic activity. Mosinska et al. (2017) reviewed the landscape of motilin and ghrelin receptor agonists in development for constipation-associated and motility-associated disorders, including camicinal, GSK962040, and other selective motilinergic compounds.[7] None has achieved FDA approval. The tachyphylaxis problem that plagues erythromycin appears to be a class effect of motilin receptor agonists, making sustained prokinetic therapy difficult with any agent acting through this pathway.
Motilin and small intestinal bacterial overgrowth (SIBO)
The MMC's housekeeping function has direct implications for small intestinal bacterial overgrowth. The small intestine normally contains relatively few bacteria compared to the colon, maintained at low levels partly by the regular sweeping action of Phase III contractions. When the MMC is disrupted, whether by diabetes, scleroderma, post-surgical adhesions, or medications that slow motility, bacteria can proliferate in the small intestine.
SIBO produces symptoms that overlap with irritable bowel syndrome: bloating, abdominal pain, diarrhea, and malabsorption. The relationship between impaired motilin signaling and SIBO has been documented in several clinical contexts. Diabetic patients with gastroparesis frequently show both absent or disordered MMC cycling and elevated small intestinal bacterial counts. Post-vagotomy patients lose the neural input that coordinates motilin release with MMC propagation.
Khalaf et al. (2018) used MRI to assess postprandial gastrointestinal motility and peptide responses in healthy volunteers, establishing baseline measurements of how motilin, ghrelin, CCK, and other peptides coordinate normal motility patterns. These imaging-based assessments provide the foundation for identifying specific motility defects in patients with SIBO and gastroparesis.[15]
The clinical implication is straightforward: if motilin-driven MMC cycling could be pharmacologically restored in patients with impaired fasting motility, the downstream consequences of bacterial overgrowth might be prevented. This is why the failure to develop a non-tachyphylactic motilin receptor agonist represents a genuine gap in gastroenterological therapeutics.
New research: motilin and appetite
Huang et al. (2025) published a study that expanded understanding of motilin's physiology beyond gut motility. Using Suncus murinus (the Asian house shrew, one of the few small animals that expresses functional motilin receptors), they demonstrated that motilin stimulates food intake in addition to gastric motility. The study used simultaneous measurement of feeding behavior and gastric contractions, showing that motilin-induced eating was linked to but not entirely dependent on gastric motor activity.[8]
This finding connects motilin to the appetite regulation network alongside ghrelin, CCK, and GLP-1. If motilin drives both the housekeeping contractions that clear the gut and the hunger signaling that prepares the organism for the next meal, the peptide may function as a bridge between the fasting motility program and the feeding initiation program. For context on how CCK signals satiety, motilin and CCK represent opposing poles of the feeding cycle: motilin activates during fasting to clean and prepare, while CCK activates during eating to signal fullness.
GLP-1 drugs and gastroparesis: the emerging concern
A recent and clinically urgent intersection involves GLP-1 receptor agonists and their effects on gastrointestinal motility. Cymbal et al. (2025) used wireless motility capsules to measure GLP-1 receptor agonist effects across the entire gut, demonstrating measurable delays in gastric emptying, small bowel transit, and colonic transit in patients taking these drugs.[9]
GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action for diabetes and obesity treatment. But this slowing can become pathological. Singhal et al. (2025) reported a case of semaglutide-induced gastroparesis following rapid dose escalation, illustrating that the same motility-slowing effect that produces satiety can, in some patients, progress to frank gastroparesis with severe nausea, vomiting, and inability to tolerate oral intake.[10]
Aneke-Nash et al. (2025) compared gastroparesis risk across different obesity treatments, including GLP-1 receptor agonists, bariatric surgery, and other modalities, finding elevated gastroparesis rates with GLP-1 drug use.[11] This concern is relevant to motilin biology because GLP-1-induced motility delay would be expected to suppress or disrupt the MMC, potentially creating the same bacterial overgrowth and stasis that MMC failure causes in other forms of gastroparesis.
Wilbrink et al. (2025) provided additional context by examining changes in gastrointestinal motility and gut hormone secretion after Roux-en-Y gastric bypass, showing that surgical alterations to gut anatomy produce complex changes in motilin, ghrelin, GLP-1, and CCK levels that collectively reshape motility patterns.[12] For the broader picture of how GLP-1 drugs affect the digestive system, see Gut Peptide Hormones: The Digestive System's Signaling Network.
The therapeutic gap
Motilin occupies an unusual position in peptide pharmacology: its biology is well understood, its clinical relevance is clear, and the proof that its receptor can be pharmacologically targeted exists (erythromycin). Yet no selective motilin receptor agonist has reached the market.
The tachyphylaxis problem is the central obstacle. When motilin receptors are continuously or repeatedly stimulated, they undergo desensitization and internalization, reducing the cell surface receptor population available for subsequent activation. This is a physiological safeguard against constitutive receptor activation, but it renders any drug that acts as a continuous motilin agonist self-defeating. Erythromycin's prokinetic effect fades within 2-4 weeks of regular dosing. The selective motilin agonists camicinal and GSK962040 showed similar tachyphylaxis in clinical development.
The species limitation compounds the problem. Because rats and mice lack functional motilin receptors, standard preclinical development pathways using rodent models are unavailable. Dogs express motilin receptors and have been used in some studies, but canine models are expensive, ethically constrained, and physiologically different from humans in ways that affect gastric motility. The Suncus murinus (Asian house shrew) model used by Huang et al. (2025) is valuable for basic research but impractical for drug development screening.
These two barriers together explain why a peptide system identified decades ago remains untargeted by approved drugs. The biological pathway is validated; the pharmacological challenge of sustained receptor engagement without desensitization is unsolved.
Perboni et al. (2010) reviewed the role of ghrelin-family peptides in appetite and motility, noting that the overlap between motilin and ghrelin signaling creates both opportunities (ghrelin agonists as indirect motilin pathway modulators) and complications (difficulty separating appetite effects from motility effects in drug development).[13]
Wang et al. (2024) added an unexpected dimension by showing that bitter-tasting drugs tune GDF15 and GLP-1 expression through motilin receptors, revealing that the motilin receptor mediates effects beyond motility that are relevant to metabolic drug development.[14]
For patients with gastroparesis, the unmet need is real. Erythromycin works acutely but loses effectiveness. Metoclopramide (a dopamine antagonist) carries the risk of tardive dyskinesia. Domperidone is restricted in many countries. Gastric electrical stimulation is invasive and has inconsistent efficacy. A selective, non-tachyphylactic motilin receptor agonist, or a drug that restores normal MMC cycling through an alternative mechanism, remains one of the most sought-after targets in gastrointestinal pharmacology. Alternative strategies under investigation include biased agonists that activate specific downstream signaling pathways without triggering full receptor internalization, and allosteric modulators that enhance the receptor's response to endogenous motilin without producing tachyphylaxis. For the peptide that controls digestive enzyme secretion downstream of motilin's cleaning wave, see Secretin and Gastrin: The Peptides That Control Your Digestive Juices. For the intestinal repair peptide that maintains the gut lining between these cycles, see GLP-2: The Intestinal Growth Factor That Repairs Your Gut Lining. For the broader regulatory peptide VIP, see Vasoactive Intestinal Peptide (VIP): The Gut's Master Regulator.
The Bottom Line
Motilin is a 22-amino-acid peptide that initiates the migrating motor complex, the gut's fasting housekeeping system that clears residual material every 90-120 minutes. The peptide acts through the motilin receptor on gastric and intestinal smooth muscle. Erythromycin's accidental discovery as a motilin receptor agonist provided both a proof-of-concept prokinetic drug and a demonstration of the receptor's druggability. Motilin is structurally related to ghrelin, and recent research suggests it also regulates appetite. Selective motilin receptor agonists have been pursued for gastroparesis but none has reached market due to tachyphylaxis. The growing prevalence of GLP-1 agonist-induced gastroparesis adds urgency to the search for effective prokinetic agents.